These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
    Author: Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE.
    Journal: J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690.
    Abstract:
    Systemic high-dose methotrexate (HD-MTX) is the most effective chemotherapeutic agent in the treatment of primary central nervous system lymphoma (PCNSL). Leptomeningeal involvement is common and intrathecal methotrexate (IT-MTX) is frequently used in combination with HD-MTX, but its benefits are not established. Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity.
    [Abstract] [Full Text] [Related] [New Search]